Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5124-8. Epub 2005 Oct 3.

Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.

Author information

1
Merck Research Laboratories, RY800-B116, PO Box 2000, Rahway, NJ 07065, USA. tim_blizzard@merck.com

Abstract

Two novel side chains which had previously been found to enhance antagonist activity in the dihydrobenzoxathiin SERM series were applied to three existing platforms. The novel side chains did not improve the antagonist activity of the existing platforms.

PMID:
16203138
DOI:
10.1016/j.bmcl.2005.08.084
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center